Health-related quality of life (HRQOL) in patients with metastatic non-squamous non-small-cell lung cancer without sensitising EGFR mutations or ALK translocations is maintained or marginally improved with the addition of pembrolizumab to standard chemotherapy. Patient reported outcomes in the international KEYNOTE-189 study of more than 600 patients, found HRQOL was maintained from baseline to week 21 ...
Quality doesn’t always match quantity of survival with pembrolizumab
By Mardi Chapman
11 Feb 2020